STRONGTROPIN HGH human growth hormone steroid 10 IU high purity for
Notice: STRONGTROPIN HGH is the genuine HGH with the best quality,
10 IU/vial. But there are some fake STRONGTROPIN HGHs in the market
now. This brand is is our company's right. Any use not from our
company is illegal. Our company will often change the top's color against the fake
one. If top's color of STRONGTROPIN you bought is not the same as
picture shows, it is fake.
Both the finished products and the raw material of HGH (191 aa) are
Purity more than 96%
The vial with lyophilised powder contains:
HGH raw material powder(191aa) .........3.7 mg
equivalent to ......... 10 IU
Excipient ......... Mannitol
Instruction for STRONGTROPIN®
Recombinant Human Growth Hormone for Injection
(Somatropin / HGH, rDNA Origin)
STRONGTROPIN® is a kind of sterile, lyophilized formulation of
Recombinant Human Growth Hormone (HGH) with 191 amino acids ,
derived from engineering E.coli, and it is identical to the natural
growth hormone in amino acid sequence and three-dimension
structure. STRONGTROPIN® is indicated for growth failure due to
endogenous growth hormone deficiency (GHD) and Turner disease or
Kidney failure. STRONGTROPIN® can be used to heal up the surgery
wound or burned wound and it has good effect to preservation for
Generic name: Recombinant human growth hormone for injection.
Trade name: STRONGTROPIN®
Composition in effect: Recombinant human growth hormone.
White loose lyophilized powder.
[PHARMACOLOGY AND TOXICOLOGY]
STRONGTROPIN® exerts the same actions of endogenous human growth
hormone. It can stimulate proliferation and differentiation of
epiphysis chondrocyte, stimulate growth of cartilage matrix cells,
stimulate proliferation and differentiation of osteoblast; thus
accelerate the liner growth rate and improve epiphysis width.
STRONGTROPIN® can promote protein synthesis in whole body; reverse
the negative nitrogen equilibrium caused by wound and surgery;
correct the hypoproteinemia due to severe infection or
hepatocirrhosis; stimulate synthesis of immune globin and
proliferation of lymphadenoid, macrophage and lymphocyte, thus
enhance the ability of infection resistance; stimulate
proliferation of collagenocyte, fibroblast and macrophage in sites
of burn and surgery, thus accelerate wound healing; promote
synthesis of cardiocytes, thus improve cardiac contractility and
reduce cardiac oxygen consumption; regulate lipometabolism, thus
depress serum cholesterol and low density lipoprotein level;
complement insufficiency or deficiency of growth hormone, regulate
adult lipometabolism, osteometabolism, heart and kidney function.
It is reported that the equal pharmacological effect could be
achieved via subcutaneous (sc) or intramuscular (IM)
administration. Even though sc may lead a higher concentration of
GH in plasma, IM could also yield the same IGF-l level. The
absorption of GH is the relatively slow, Cmax often occurs at 3-5
hours after injection. Clearance of GH is via liver and kidney, the
half-life of clearance is about 2-3 hours. Uncatabolized GH
excreted in urea is almost immeasurable. All of the GH in
circulation system exists as a complex form with GH binding
proteins that make the half-life of GH prolonged.
STRONGTROPIN® is indicated for the growth failure of children due
to endogenous growth hormone deficiency (GHD).
More indication and usage
Exercise and body Building
Increased Brain Function
Superior Immune Function
Improve Cholesterol Prodfile
Faster Wound Healing
Increase Sexual Llibido
Increase Bone Density
When reconstitution 1 ml sterile water for injection should be
injected along the bottle wall, then swirl the vial with gentle
rotary motion until the contents are completely dissolved, do not
The recommended dosage of STRONGTROPIN® for the treatment of
children growth failure is 0.1~0.15IU/kg daily subcutaneous
administration for 3 months to 3 years. Therapy regimen could be
modified according to experienced doctors’ suggestion.
The recommended dosage of STRONGTROPIN® for the treatment of severe
burn is 0.2~0.14IU/kg daily subcutaneous administration for 2
Growth hormone may cause transient hyperglycemia; it can be
recovered as the administration proceeded or terminated.
Adverse reactions occurred in about 1% short stature children in
clinical trial. Common adverse reactions include slight pain,
tingle, turgescence around the injection site and peripheral edema,
arthralgias. All of those adverse reactions often occurred at the
beginning of treatment, and were temporal and tolerable. Long-term
and high dosage administration of rhGH may develop the antibodies
in a few patients. However, the antibodies concentration could be
rarely up to as high as 2 mg/L that might affect the therapeutic
1. STRONGTROPIN® should not be used in patients whose epiphysis had
2. STRONGTROPIN® should not be used in cancer patients with active
neoplasia. GH therapy should be discontinued if evidence of
3. STRONGTROPIN® should not be used in patients in acute shock
stage with severe infection.
[WARNINGS AND PRECAUTIONS]
1. rhGH therapy should be conducted on exactly diagnosed GHD
patients under advice of experienced doctor.
2. For diabetes patients, dosage of anti-glucourea drugs should be
adjusted during rhGH therapy.
3. For patients whose GHD were caused by encephaloma or encephalic
wound, the progress and relapse possibility of potential diseases
should be closely monitored.
4. For ACTH deficiency patients, dosage of ATCH should be adjusted
because the growth improvement effect of rhGH could be inhibited by
simultaneous using of ACTH.
5. Thyroid gland function should be tested regularly because
clinical hypothyroidism may occur to some patients during rhGH
therapy. For those hypothyroid, thyroid supplementation is
necessary for ensuring the therapeutic effects of rhGH.
6. Careful consideration should be taken if claudicating occurred
during rhGH therapy because the patients who suffered from
endocrine system disease (including GHD) have such a tendency that
their epiphysis plates of femur are relatively easy to separate.
7. Growth hormone may lead to over insulin state, attention should
be paid to if lower glucose intolerance appeared.
8. Do not take over-dose of rhGH, one time over-dose rhGH
administration can lead to low blood sugar and succeeded with high
blood sugar. Long-term over-does rhGH administration can lead to
9. Injection site should often variation in case lipoatrophy.
[PREGNANT AND BABY-NURSING WOMEN USAGE]
It is not recommended for pregnant and nursing women to accept rhGH
Response to rhGH of children is similar to that of adults in
pharmacology, toxicology and pharmacokinetics, rhGH is safe for
Response to rhGH of old patients is similar to that of adults in
pharmacology, toxicology and pharmacokinetics, rhGH is safe for
Responses to rhGH therapy might be inhibited by glucocorticoid, so
that hydrocortisone dosage would be lower than 10~15mg/m2 of body
surface during rhGH therapy.
Simultaneous using of non-androgenic steroid during rhGH therapy
can accelerate growth rate.
There is yet no report about over dosage of rhGH; however, over
dosage may cause some side effect, such as hypoglycemia at the
beginning then succeeded with hyperglycemia. Long-term over dosage
using of rhGh can lead to acromegaly.
Keep at 2~8ºC away from light. The reconstituted solution mixed
with Sterile Water for injection is advised be stored at 2~8ºC for
48 hours, do not be frozen.